tiprankstipranks
Trending News
More News >
Repligen (CH:RGN)
:RGN
Advertisement

Repligen (RGN) Price & Analysis

Compare
0 Followers

RGN Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Geographic And Segment ExpansionHighlights for 3Q25 for Repligen included sales growth in all geographic areas and business segments, especially Asia-Pacific with 50% growth.
Revenue GrowthRepligen reported solid 3Q25 operational results, delivering outperformance from both a revenue and earnings perspective.
Strategic PartnershipsRepligen established a strategic partnership with Novasign to develop and integrate Novasign’s digital twin capabilities into Repligen filtration systems.
Bears Say
Earnings Growth ChallengesHigher fixed costs and higher contributions from recent acquisitions and new products may dampen earnings growth in the near future despite expected revenue growth.
Margin PressuresThe forecast for 2025 adjusted operating margin and adjusted EBITDA margin has been lowered, indicating some financial headwinds.
Market SentimentShares ended the day down nearly 6%, attributed to the EBITDA/EPS guide-down and management signaling that elevated operating expense levels will continue near term.

Repligen News

RGN FAQ

What was Repligen’s price range in the past 12 months?
Currently, no data Available
What is Repligen’s market cap?
Repligen’s market cap is CHF6.68B.
    When is Repligen’s upcoming earnings report date?
    Repligen’s upcoming earnings report date is Feb 25, 2026 which is in 111 days.
      How were Repligen’s earnings last quarter?
      Repligen released its earnings results on Oct 28, 2025. The company reported $0.372 earnings per share for the quarter, beating the consensus estimate of $0.341 by $0.031.
        Is Repligen overvalued?
        According to Wall Street analysts Repligen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Repligen pay dividends?
          Repligen does not currently pay dividends.
          What is Repligen’s EPS estimate?
          Repligen’s EPS estimate is 0.36.
            How many shares outstanding does Repligen have?
            Currently, no data Available
            What happened to Repligen’s price movement after its last earnings report?
            Repligen reported an EPS of $0.372 in its last earnings report, beating expectations of $0.341. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Repligen?
              Currently, no hedge funds are holding shares in CH:RGN

              Company Description

              Repligen

              Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

              Repligen (RGN) Earnings & Revenues

              RGN Earnings Call

              Q3 2025
              0:00 / 0:00
              Earnings Call Sentiment|Positive
              The earnings call reflects a strong performance with significant organic growth, record order growth, and improved financial guidance. However, challenges remain, particularly with the China market and gene therapy headwinds. Despite these challenges, the company is optimistic about its strategic investments and future growth opportunities.View all CH:RGN earnings summaries

              RGN Revenue Breakdown

              44.00%44.00%37.00%19.00%
              44.00% North America
              37.00% Europe
              19.00% APAC/Other
              tipranks
              Similar Stocks
              Company
              Price & Change
              Follow
              AptarGroup
              Merit Medical Systems
              Teleflex
              Stevanato Group
              Bausch + Lomb Corporation

              Options Prices

              Currently, No data available
              ---
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis